Aspirantskiy Vestnik PovolzhiyaAspirantskiy Vestnik Povolzhiya2072-23542410-3764Samara State Medical University2421710.17816/2075-2354.2018.18.153-160Research ArticleEXPERIMENTAL MODELING AND FUTURE DIRECTIONS OF HOMEOSTASIS CORRECTION IN INFLAMMATORY BOWEL DISEASESOsikovMV VDoctor of Medicine, Professor, Head of Department of Pathological Physiology.prof.osikov@yandex.ruSimonyanE VCandidate of Pharmaceutical Sciences, Associate Professor, head of the Department of pharmacy and chemistry, faculty of pharmacy.elenasimonian@yandex.ruBakeevaA ELaboratory assistant, Department of Pharmacy and Chemistry, Pharmaceutical Faculty.a.kurenkova01@yandex.ruBoykoM SAssistant of the Pathological Physiology Department.ri-tochka9@list.ruBivalkevichV AStudent of the Medical Faculty.bivalkevichva@gmail.comSouth Ural state medical University15032018181-215316011032020Copyright © 2018, Osikov M.V., Simonyan E.V., Bakeeva A.E., Boyko M.S., Bivalkevich V.A.2018Inflammatory bowel disease (IBD) - Crohn’s disease (CD) and ulcerative colitis (UC) are chronic diseases with an unknown etiology and pathogenesis. The medical treatment of such pathologies causes lots of adverse effects and usually doesn’t lead to the persistent remission. Studying of an etiology and pathogenesis, improvement of methods of treatment of IBD dictates need of adequate experimental modeling of UC and CD. The purpose of the article is to make an analysis of the literature, indexed in Pubmed, Medline, Russian Science Citation Index, dedicated to the IBD modeling and perspective ways of homeostasis correction during such pathologies as CD and UC. The oxazo-lone injection was determined as the most optimal way of UC modeling and the injection of trinitrobenzensulfonic acid (TNBS) for CD modeling. Economical and clinical benefits of oxazolone and TNBS usage, the results of clinical and preclinical studies and adverse events of Aloe vera, Boswellia serrata, Trigonella foenum-graecum, Andrographis paniculata, omega 3 fatty acids, Ulmus fulva, Potentilla erecta, liquorice, coenzyme Q10, vitamin B12, Cucruma longa and vitamin D are described in the analyzed literature. The critical literature analysis gives us an ability to distinguish vitamin D and Cucruma longa as perspective therapeutic agents for the development of the pharmaceuticals with anti-inflammatory, immunomodulatory and composite antioxidant effects, for UC and CDs’ treatment, causing the minimum of adverse effects. Suppositories were determined as the most optimal and perspective dosage form, used for the IBD treatment, according to the best biofarmaceutical features among the other forms.ulcerative colitisCrohn’s diseasemodelingexperimental therapyязвенный колитболезнь Кронамоделированиеэкспериментальная терапия[Алексеева О.П., Колодей Е.Н. Сравнительная оценка течения, диагностики и лечения воспалительных заболеваний кишечника в Нижегородской области 2014-2015 и 2009-2010 гг. // Медицинский альманах. - 2017. - № 1 (46). - С. 33-36][Ткачев А.В., Мкртчян Л.С., Никитина К.Е., Волынская Е.И. Воспалительные заболевания кишечника: на перекрестке проблем // Практическая медицина. - 2012. - № 3 (58). - С. 17-22][Гайдарова А.П., Корощенко Г.А., Айзман Р.И. Влияние куркумы и куркумина на углеводный обмен при аллоксан-индуцированном сахарном диабете у крыс // Современные проблемы науки и образования. - 2014. - № 5. - С. 597][Гончарик И.И. Болезнь Крона // УО «Белорусский государственный медицинский университет». -2013. - № 1. - C. 113-117][Дударева Л.В., Борисов М.Ю., Серебрякова А.Д. Разработка методик качественного и количественного определения куркуминоидов в корневищах куркумы длинной // Материалы научно-практической конференции «Аспирантские чтения - 2016: Молодые ученые - от технологий XXI века к практическому здравоохранению». - Самара, 2016. -С. 41][Каленикова Е.И., Харитонова Е.В., Городецкая Е.А., и др. Редокс-статус и фармакокинетика коэнзима Q10 в плазме крови крысы после его однократного внутривенного введения // Биомедицинская химия. - 2015. - Т. 61. - № 1. - С. 125-131][Визе-Хрипунова М.А., Каширина А.Н., Муканеева Д.К., и др. Клинико-эндоскопическая характеристика воспалительных заболеваний кишечника // Ульяновский медико-биологический журнал. -2014. - № 4. - С. 38-44][Осиков М.В. Влияние альфа1-кислого гликопротеина на процессы свободнорадикального окисления при экспериментальной печеночной недостаточности // Бюллетень экспериментальной биологии и медицины. - 2007. - Т. 144. - № 7. - С. 29-31][Койнова И.А., Белобородова Е.В., Бурковская В.А., и др. Особенности течения воспалительных заболеваний кишечника в зависимости от психологического статуса пациента // Современные проблемы науки и образования. - 2016. - № 6][Осиков М.В., Ахматов В.Ю., Телешева Л.Ф., и др. Плейотропные эффекты эритропоэтина при хронической почечной недостаточности // Фундаментальные исследования. - 2013. - № 7-1. - С. 218-224][Плудовски П., Карчмаревич Э., Байер М., и др. Практические рекомендации по поступлению витамина D и лечению его дефицита в Центральной Европе - Рекомендуемое потребление витамина D среди населения в целом и в группах риска по дефициту витамина D // Журнал ГрГМУ. - 2014. -№ 2 (46). - С. 109-118][Фаттал А. Экспериментальное обоснование использования таблеток экстракта коры осины при язвенных заболеваниях кишечника: автореф. дис. ... канд. фарм. наук. - Харьков, 2016. - С. 13-33][Харитонов А.Г. Эффективность и безопасность применения ведолизумаба при болезни крона (обзор литературы) // Колопроктология. - 2017. -№ 3. - С. 71-79][Ardesia M, Ferlazzo G, Fries W. Vitamin D and Inflammatory Bowel Disease. BiomedRes Int. 2015;2015:470805. doi: 10.1155/2015/470805][Barzegar A, Moosavi-Movahedi AA. Intracellular ROS protection efficiency and free radical-scavenging activity of curcumin. PLoS One. 2011;6(10):e26012. doi: 10.1371/journal.pone.0026012][Bhanu Priya K, Venkata Subbaiah Kotakadi, Josthna P. Anti-inflammatory Effect of Basella rubra on Oxazolone-induced Colitis in Rat. American Journal of Phytomedicine and Clinical Therapeutics. 2016;7(2):832-841][Yang M, et al. Binding of Curcumin with Bovine Serum Albumin in the Presence of iota-Carrageenan and Implications on the Stability and Antioxidant Activity of Curcumin. J Agric Food Chem. 2013;61(29):7150-7155. doi: 10.1021/jf401827x][Hartmann MR, Fillmann HS, Martins MI, et al. Boswellia serrata has beneficial anti-inflammatory and antioxidant properties in a model of experimental colitis. PhytotherRes. 2014;28(9):1392-1398. doi: 10.1002/ ptr.5142][Cabre E, Manosa M, Gassull MA. Omega-3 fatty acids and inflammatory bowel diseases - a systematic review. Br J Nutr. 2012;(107 Suppl 2):S240-52. doi: 10.1017/S0007114512001626][Liu L, Liu YL, Liu GX, et al. Curcumin ameliorates dextran sulfate sodium-induced experimental colitis by blocking STAT3 signaling pathway. Int Immunopharmacol. 2013;17(2):314-320. doi: 10.1016/j. intimp.2013.06.020][Vecchi Brumatti L, Marcuzzi A, Tricarico PM, et al. Curcumin and Inflammatory Bowel Disease: Potential and Limits of Innovative Treatments. Molecules. 2014;19(12):21127-21153. doi: 10.3390/ molecules191221127][Murakami A, Furukawa I, Miyamoto S, et al. Curcumin combined with turmerones, essential oil components of turmeric, abolishes inflammation-associated mouse colon carcinogenesis. Biofactors. 2013;39(2):221-232. doi: 10.1002/biof.1054][Epstein J, Docena G, MacDonald TT, Sanderson IR, et al. Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1 beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Br J Nutr. 2010;103(6):824-832. doi: 10.1017/ S0007114509992510][Saxena A, Kaur K, Hegde S, et al. Dietary Agents and Phytochemicals in the Prevention and Treatment of Experimental Ulcerative Colitis. J Tradit Complement Med. 2014;4(4):203-217. doi: 10.4103/2225-4110.139111][Toden S, Theiss AL, Wang X, Goel A. Essential turmeric oils enhance anti-inflammatory efficacy of curcumin in dextran sulfate sodium-induced colitis. Sci Rep. 2017;7(1):814. doi: 10.1038/s41598-017-00812-6.][Laverny G, Penna G, Vetrano S, et al. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol Lett. 2010;131(1):49-58. doi: 10.1016/j.imlet.2010.03.006][Engel MA, Khalil M, Siklosi N, et al. Opposite effects of substance P and calcitonin generelated peptide in oxazolone colitis. Dig Liver Dis. 2012;44(1):24-29. doi: 10.1016/j.dld.2011.08.030][Ewees MG, Messiha BA, Abo-Saif AA, Abd El-Latif HA. Is Coenzyme Q10 Effective in Protection against Ulcerative Colitis? An Experimental Study in Rats. Biol Pharm Bull. 2016;39(7):1159-1166. doi: 10.1248/bpb. b16-00124][Denadai R, Teixeira FV, Steinwurz F, et al. Induction or exacerbation of psoriatic lesions during anti-TNF-a therapy for inflammatory bowel disease: A systematic literature review based on 222 cases. J Crohns Colitis. 2013;7(7):517-524. doi: 10.1016/j.crohns.2012.08.007][Uyanikoglu A, Ermis F, Akyuz F, et al. Infliximab in inflammatory bowel disease: Attention to adverse events. Eur Rev Med Pharmacol Sci. 2014;18(16):2337-2342][Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195-218. doi: 10.1208/s12248-012-9432-8][Ke F, Yadav PK, Ju LZ. Herbal Medicine in the Treatment of Ulcerative Colitis. Saudi J Gastroenterol. 2012;18(1):3-10. doi: 10.4103/1319-3767.91726][Kiesler P, Fuss IJ, Strober W. Experimental Models of Inflammatory Bowel Disease. Cell Mol Gastroenterol Hepatol. 2015;1(2):154-170. doi: 10.1016/j.jcmgh.2015.01.006][Molodecky NA, Soon IS, Rabi DM. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on cyctematic review. Gastroenterology. 2012;142(1):46-54.e42. doi: 10.1053/j. gastro.2011.10.001][El Morsy EM, Kamel R, Ahmed MA. Attenuating effects of coenzyme Q10 and amlodipine in ulcerative colitis model in rats. Immunopharmacol Immunotoxicol. 2015;37(3):244-251. doi: 10.3109/08923973.2015. 1021357][Nejatzadeh-Barandoz F. Antibacterial activities and antioxidant capacity of Aloe vera. Org Med Chem Lett. 2013;3(1):5. doi: 10.1186/2191-2858-3-5][Nolte T, Zadeh-Khorasani M, Safarov O, et al. Oxazolone and ethanol induce colitis in non-obese diabetic-severe combined immunodeficiency interleukin-2Rvnuli mice engrafted with human peripheral blood mononuclear cells. Clin Exp Immunol. 2013;172(2):349-362. doi: 10.1111/cei.12057][Shao J, Liu Z, Wang L, et al. Screening of the optimized prescription from Suqingwan in terms of its therapeutic effect on DSS-induced ulcerative colitis by its regulation of inflammatory and oxidative mediators. J Ethnopharmacol. 2017;202:54-62. doi: 10.1016/j. jep.2017.03.006][Yang H, Du Z, Wang W, et al. Structure and Activity Relationship of Curcumin: Role of Methoxy Group in Anti-inflammatory and Anti-colitis Effects of Curcum-in. J Agric Food Chem. 2017;65(22):4509-4515. doi: 10.1021/acs.jafc.7b01792][Yang L, Weaver V, Smith JP, et al. Therapeutic effect of vitamin D supplementation in a pilot study of Crohn’s patients. Clin Transl Gastroenterol. 2013;4:e33. doi: 10.1038/ctg.2013.1][Suskind DL, Wahbeh G, Burpee T, et al. Tolerability of curcumin in pediatric inflammatory bowel disease: A forced-dose titration study. J Pediatr Gastroenterol Nutr. 2013;56(3):277-279. doi: 10.1097/ MPG.0b013e318276977d][Martin R, Chain F1, Miquel S, et al. Using murine colitis models to analyze probiotics-host interactions. FEMS Microbiol Rev. 2017;41(Supp_1):S49-S70. doi: 10.1093/ femsre/fux035][Battat R, Kopylov U, Szilagyi A, et al. Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management. In-flamm Bowel Dis. 2014;20(6):1120-1128. doi: 10.1097/ MIB.0000000000000024][Zherebiatiev A., Kamyshnyi A. Expression Levels of Proinflammatory Cytokines and NLRP3 Inflammasome in an Experimental Model of Oxazolone-induced Colitis. Iran J Allergy Asthma Immunol. 2016;15(1):39-45]